[go: up one dir, main page]

MX2022013502A - Materiales y métodos para tratar la artritis de idiopática juvenil. - Google Patents

Materiales y métodos para tratar la artritis de idiopática juvenil.

Info

Publication number
MX2022013502A
MX2022013502A MX2022013502A MX2022013502A MX2022013502A MX 2022013502 A MX2022013502 A MX 2022013502A MX 2022013502 A MX2022013502 A MX 2022013502A MX 2022013502 A MX2022013502 A MX 2022013502A MX 2022013502 A MX2022013502 A MX 2022013502A
Authority
MX
Mexico
Prior art keywords
idiopathic arthritis
juvenile idiopathic
methods
materials
treating juvenile
Prior art date
Application number
MX2022013502A
Other languages
English (en)
Inventor
Jocelyn Leu
Michael Clark
Zhenhua Xu
Karen Bensley
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2021/053429 external-priority patent/WO2021220140A1/en
Publication of MX2022013502A publication Critical patent/MX2022013502A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos que usan anticuerpos anti-TNF, p. ej., el anticuerpo anti-TNF golimumab que tiene una cadena pesada (HC) que comprende una secuencia de aminoácidos de la SEQ ID NUM:36 y una cadena ligera (LC) que comprende una secuencia de aminoácidos de la SEQ ID NUM:37, para usar en el tratamiento de la artritis idiopática juvenil (JIA) y, en particular, para la artritis idiopática poliarticular juvenil (pJIA).
MX2022013502A 2020-04-27 2021-04-26 Materiales y métodos para tratar la artritis de idiopática juvenil. MX2022013502A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063015902P 2020-04-27 2020-04-27
US202063015889P 2020-04-27 2020-04-27
US202063015894P 2020-04-27 2020-04-27
PCT/IB2021/053429 WO2021220140A1 (en) 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis

Publications (1)

Publication Number Publication Date
MX2022013502A true MX2022013502A (es) 2023-02-01

Family

ID=78336251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013502A MX2022013502A (es) 2020-04-27 2021-04-26 Materiales y métodos para tratar la artritis de idiopática juvenil.

Country Status (9)

Country Link
EP (1) EP4143226A4 (es)
JP (1) JP2023524668A (es)
KR (1) KR20230005284A (es)
CN (1) CN115461365A (es)
AU (1) AU2021263136A1 (es)
BR (1) BR112022021766A2 (es)
CA (1) CA3127807A1 (es)
IL (1) IL297623A (es)
MX (1) MX2022013502A (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007014440A (es) * 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CN110234351A (zh) * 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法

Also Published As

Publication number Publication date
EP4143226A1 (en) 2023-03-08
KR20230005284A (ko) 2023-01-09
IL297623A (en) 2022-12-01
AU2021263136A1 (en) 2023-01-05
CN115461365A (zh) 2022-12-09
BR112022021766A2 (pt) 2022-12-13
CA3127807A1 (en) 2021-10-27
JP2023524668A (ja) 2023-06-13
EP4143226A4 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
WO2022204316A3 (en) Variant nucleic acid libraries for cd3
MY207353A (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
RU2009118621A (ru) Агонистические антитела против notch3 и их применение для лечения ntch3-ассоциированных заболеваний
DE60334141D1 (de) VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
SI2481753T1 (en) Anti-IL-17 antibodies
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
NZ596295A (en) Anti-5T4 antibodies and uses thereof
NZ594968A (en) Humanized c-kit antibody
NZ598770A (en) Monoclonal antibodies
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
IL177337A0 (en) Less immunogenic binding molecules
FI981799L (fi) DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ZA202304591B (en) Anti-cd73 antibody and use thereof
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
WO2021050857A8 (en) Anti-cd371 antibodies and uses thereof
MX2022001068A (es) Anticuerpo anti-il17a humanizado y uso del mismo.
ZA202400787B (en) Pharmaceutical composition and use
TN2018000358A1 (en) Humanized anti-basigin antibodies and the use thereof.
PH12021550945A1 (en) ANTI-HUMAN Fn14 ANTIBODY
ZA202503670B (en) Anti-cd16a antibody and application thereof
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
BR112023025884A2 (pt) Proteína de fusão de domínio de ligante de anticorpo de nkg2d
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO